OSR Health postpones 2026 annual meeting, no new date set

OSR Health, Inc. said in a Form 8-K dated June 5, 2026, and filed June 11, 2026, that its board of directors decided to postpone the company's 2026 Annual Meeting of Stockholders. The meeting had been scheduled for June 18, 2026. The board said additional time is needed to evaluate certain matters relating to the meeting and to the business to be presented to stockholders. The board determined that postponement is in the best interests of the company and its stockholders.

The company has not set a new date. It said it intends to announce the rescheduled date, time and related information in a later filing with the Securities and Exchange Commission and through other appropriate communications. The 8-K is filed under Item 8.01, other events, and the company says it had previously filed a definitive proxy statement on Schedule 14A for the meeting. Stockholders are encouraged to read the proxy materials and any supplements, which the company says are available free of charge on the SEC website and on its own website.

A note on the company's name

The 8-K names the registrant as OSR Holdings, Inc. This article uses the company's current name, OSR Health, Inc. The 8-K identifies the registrant as a Delaware corporation with its principal offices in Bellevue, Washington.

The company and its business

OSR Health describes itself as a global healthcare holding company with operations in South Korea and Switzerland and an office in the United States. Its annual report for 2025, filed March 31, 2026, says the company aims to identify, lead and support subsidiaries and subsidiary candidates. Those are built on innovative research, and the company may acquire or license assets from industry or academia to create them.

The report lists three subsidiaries, two with their own drug development pipelines. One is developing oral T-cell immunotherapies using a live attenuated bacterial vaccine strain. Another is developing a design-augmented recombinant biologic for bone and cartilage regeneration, and the third makes neurovascular surgical devices.

The business behind the portfolio

The annual report says the subsidiaries pursue diverse scientific and technological developments in distinct areas of therapeutics research and development, including oral T-cell immunotherapies and recombinant biologics. In the company's view, that spread gives it a broader scope of potential therapeutic solutions and reduces the risks of a single-asset approach. The report says the company collaborates with academic and industry leaders and encourages knowledge sharing among its subsidiaries.

The report also describes the intellectual property position. As of December 31, 2025, the subsidiaries' patent portfolio included 10 patent families of issued patents and pending applications. Those are pending or issued in multiple jurisdictions, including the United States, Europe, Japan, India and China, with anticipated expirations between 2032 and 2041.

Financial position

SEC XBRL data show revenue of $2.9 million for fiscal 2025, compared with $3.5 million for fiscal 2024. Research and development expense was $318,446 in 2025 and $161,155 in 2024. Cash from operations was negative $4.3 million in 2025 and negative $1.8 million in 2024. The fiscal 2024 net loss was $2.4 million, and year-end 2024 cash and cash equivalents were $341,543.

The risks ahead

The company has not set a new meeting date, and the 8-K does not say what the board still has to evaluate or why more time is needed. Stockholders have no vote on the proxy items until a new date is announced. The 2025 annual report describes a holding company whose cash from operations was negative $4.3 million in 2025, against negative $1.8 million a year earlier, with revenue of $2.9 million after $3.5 million in 2024. The company says it intends to announce the rescheduled date in a later SEC filing and through other communications.

Report an error

Companies in this story

OSRHOSR Health, Inc.OTC · United StatesOpen the starter desk